Ethanobicyclic amine derivatives for CNS disorders

A pharmaceutical composition comprising a therapeutically-effective amount of an active compound for treating or preventing a psychotic disorder, a convulsive disorder, a dystonic disorder or cerebral ischemia, and a pharmaceutically-acceptable carrier or diluent, said active compound selected from a family of compounds of the formula ##STR35## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, benzyl, phenyl, alkoxy, halo and haloalkyl;

• wherein each of R.sup.5 and R.sup.6 is independently selected from hydrido, alkyl, fluoroalkyl, benzyl and phenyl;
• wherein each of R.sup.16 through R.sup.21 is independently selected from hydrido, hydroxy, alkyl, benzyl, phenyl, alkoxy, fluoroalkyl and fluoro;
• wherein any foregoing alkyl radical, alone or within another radical, is selected from alkyl radicals of one to ten carbon atoms;
• wherein m is one or two;
• wherein p is zero or one;
• or a pharmaceutically-acceptable salt thereof.

A method for treating a patient afflicted with or susceptible to a psychotic disorder, a convulsive disorder, dystonia or cerebral ischemia, which method comprises administering to the patient a therapeutically-effective amount of a compound of the formula ##STR36## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, benzyl, phenyl, alkoxy, halo and haloalkyl;

• wherein each of R.sup.5 and R.sup.6 is independently selected from hydrido, alkyl, fluoroalkyl, benzyl and phenyl;
• wherein each of R.sup.16 through R.sup.21 is independently selected from hydrido, hydroxy, alkyl, benzyl, phenyl, alkoxy, fluoroalkyl and fluoro;
• wherein any foregoing alkyl radical, alone or within another radical, is selected from alkyl radicals of one to ten carbon atoms;
• wherein m is one or two;
• wherein p is zero or one;
• or a pharmaceutically-acceptable salt thereof.